$
3.011
-0.099(-3.183%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.200
Open
3.070
VWAP
3.05
Vol
25.78K
Mkt Cap
7.67M
Low
3.000
Amount
78.62K
EV/EBITDA(TTM)
--
Total Shares
16.82M
EV
4.61M
EV/OCF(TTM)
--
P/S(TTM)
1.16
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Show More
1 Analyst Rating
down Image
-0.37% Downside
Wall Street analysts forecast BMRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRA is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
down Image
-0.37% Downside
Current: 3.011
sliders
Low
3.00
Averages
3.00
High
3.00
No Data

Valuation Metrics

The current forward P/E ratio for Biomerica Inc (BMRA.O) is 0.97, compared to its 5-year average forward P/E of 9.25. For a more detailed relative valuation and DCF analysis to assess Biomerica Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
9.25
Current PE
0.97
Overvalued PE
43.55
Undervalued PE
-25.04

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
3.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.05
Undervalued EV/EBITDA
-7.38

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
3.05
Current PS
0.30
Overvalued PS
5.70
Undervalued PS
0.40

Financials

Annual
Quarterly
FY2025Q3
YoY :
+10.03%
1.12M
Total Revenue
FY2025Q3
YoY :
-39.50%
-1.21M
Operating Profit
FY2025Q3
YoY :
-39.36%
-1.16M
Net Income after Tax
FY2025Q3
YoY :
-47.25%
-0.48
EPS - Diluted
FY2025Q3
YoY :
-42.27%
-1.05M
Free Cash Flow
FY2025Q3
YoY :
-111.60%
1.70
Gross Profit Margin - %
FY2025Q3
YoY :
-24.22%
-75.47
FCF Margin - %
FY2025Q3
YoY :
-44.89%
-103.93
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

BMRA News & Events

Events Timeline

2025-07-02 (ET)
2025-07-02
08:11:50
Biomerica announces inFoods IBS received CPT PLA code
select
2025-06-26 (ET)
2025-06-26
08:26:19
Biomerica announces appointment of Madel as Chief Commercial Officer
select
2025-06-05 (ET)
2025-06-05
08:23:15
Biomerica announces publication of data from inFoods IBS clinical study
select
Sign Up For More Events

News

9.0
07-02NASDAQ.COM
Biomerica Secures PLA Code For InFoods IBS Test, Advancing Reimbursement Access
5.0
06-26Newsfilter
Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer
5.0
06-06Newsfilter
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Sign Up For More News

FAQ

arrow icon

What is Biomerica Inc (BMRA) stock price today?

The current price of BMRA is 3.011 USD — it has decreased -3.18 % in the last trading day.

arrow icon

What is Biomerica Inc (BMRA)'s business?

arrow icon

What is the price predicton of BMRA Stock?

arrow icon

What is Biomerica Inc (BMRA)'s revenue for the last quarter?

arrow icon

What is Biomerica Inc (BMRA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Biomerica Inc (BMRA)'s fundamentals?

arrow icon

How many employees does Biomerica Inc (BMRA). have?

arrow icon

What is Biomerica Inc (BMRA) market cap?